Article Link: FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction

KENILWORTH, N.J.–(BUSINESS WIRE) January 20, 2021– Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Verquvo, a soluble guanylate cyclase (sGC)…

Source: FDA New Drug Approvals